```html

Quantitative Sudomotor Axon Reflex Test (QSART) Abnormality – A Complete Medical Guide

Overview

The Quantitative Sudomotor Axon Reflex Test (QSART) is a specialized autonomic laboratory test that measures the amount of sweat produced in response to a small acetylcholine‑mediated stimulus. An “abnormal QSART” means that the sweat output is either too low (hypohidrosis) or too high (hyperhidrosis) compared with age‑adjusted norms, indicating dysfunction of the post‑ganglionic sudomotor nerves.

Who it affects

• Adults with suspected autonomic neuropathies – e.g., diabetes, Parkinson’s disease, multiple system atrophy.
• Patients with rare hereditary disorders such as hereditary sensory and autonomic neuropathy (HSAN) or autoimmune dysautonomia.
• Individuals with unexplained orthostatic intolerance, fainting, or chronic pain syndromes may undergo QSART as part of a broader work‑up.

Prevalence

Exact prevalence of abnormal QSART results is difficult to pin down because the test is performed primarily in specialty centers. However, autonomic neuropathy—one of the most common reasons for an abnormal QSART—affects:

• ≈30–50 % of patients with long‑standing type 1 or type 2 diabetes mellitus (American Diabetes Association, 2023).
• ≈10 % of individuals with Parkinson’s disease (Mayo Clinic, 2022).
• ≈5 % of patients with chronic autoimmune conditions such as Sjögren’s syndrome (Cleveland Clinic, 2021).

Symptoms

Because the QSART evaluates sudomotor (sweat‑producing) nerves, the symptom profile mirrors conditions that alter sweating and the autonomic system. Not everyone with an abnormal test will have obvious signs, but common manifestations include:

Reduced or absent sweating (hypohidrosis)

• Dry skin – especially on the palms, soles, or face.
• Heat intolerance – feeling overheated even in modest temperatures.
• Exercise intolerance – rapid fatigue or dizziness during physical activity because the body cannot dissipate heat.
• Frequent constipation or urinary retention – reflects broader autonomic dysfunction.

Excessive sweating (hyperhidrosis)

• Profuse, localized sweating – often in the hands, feet, underarms, or forehead.
• Night sweats – damp bedding without fever.
• Emotional distress – anxiety about visible sweating.

Associated autonomic symptoms

• Orthostatic dizziness or fainting (postural orthostatic tachycardia syndrome – POTS).
• Rapid heart rate (tachycardia) when standing.
• Gastrointestinal dysmotility – nausea, bloating, or diarrhea.
• Sexual dysfunction – erectile dysfunction in men, vaginal dryness in women.
• Blood pressure fluctuations – episodes of hypertension or hypotension.

Causes and Risk Factors

Abnormal QSART results are a marker of sudomotor nerve dysfunction, not a disease itself. The underlying causes fall into several categories.

Metabolic and endocrine disorders

• Diabetes mellitus – chronic hyperglycemia damages small unmyelinated fibers (the “small‑fiber neuropathy”).
• Thyroid disease – both hypo‑ and hyperthyroidism can alter sweat gland activity.

Neurodegenerative diseases

• Parkinson’s disease, multiple system atrophy, Lewy body dementia – progressive loss of autonomic pathways.

Autoimmune and inflammatory conditions

• Sjögren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis – immune‑mediated attack on peripheral nerves.
• Autoimmune autonomic ganglionopathy (antibodies against ganglionic acetylcholine receptors).

Genetic/hereditary neuropathies

• Hereditary sensory and autonomic neuropathies (HSAN types I–IV).
• Familial dysautonomia (Riley‑Day syndrome).

Toxic exposures

• Chronic alcohol abuse.
• Chemotherapeutic agents (e.g., vincristine, cisplatin).
• Heavy metals such as lead or mercury.

Other risk factors

• Age – small‑fiber function declines modestly after age 60.
• Obesity – associated with metabolic syndrome and insulin resistance.
• Smoking – contributes to peripheral vascular and nerve damage.

Diagnosis

Diagnosing an “abnormal QSART” involves a structured work‑up that includes clinical history, physical examination, and a battery of tests.

1. Clinical assessment

• Detailed symptom questionnaire (e.g., Composite Autonomic Symptom Score – COMPASS‑31).
• Focused neurological exam looking for loss of temperature sensation, pinprick, or ankle reflexes.

2. Quantitative Sudomotor Axon Reflex Test (QSART)

1. Preparation – patient avoids caffeine, nicotine, and vigorous exercise for 12 hours; skin is cleaned.
2. Procedure – a small iontophoretic current delivers acetylcholine to four standard sites (forearm, proximal leg, distal leg, foot). Sweat output is recorded over 5–10 minutes.
3. Interpretation – results are compared with age‑ and gender‑matched normative data. Values < 50 % of expected suggest hypohidrosis; > 150 % suggest hyperhidrosis.

3. Complementary autonomic tests

• Heart‑rate variability with deep breathing.
• Valsalva maneuver.
• Tilt‑table testing for orthostatic intolerance.
• Thermoregulatory sweat test (TST) – a global map of sweating using a powder that changes color with moisture.

4. Laboratory work‑up to identify cause

• HbA1c and fasting glucose – screen for diabetes.
• Thyroid panel (TSH, free T4).
• Autoantibodies (ANA, anti‑SSA/SSB, ganglionic acetylcholine receptor antibodies).
• Vitamin B12, folate, and serum protein electrophoresis.

5. Imaging (when indicated)

• MRI of brain or spine – rule out structural lesions.
• Ultrasound of peripheral nerves – assesses nerve caliber.

Treatment Options

Therapy is two‑pronged: (1) address the underlying disease and (2) manage the sudomotor symptoms directly.

Managing the underlying cause

• Diabetes – tight glycemic control (target HbA1c < 7 %) can halt or modestly improve small‑fiber neuropathy (DCCT/EDIC study, 2022).
• Autoimmune disease – immunomodulators such as corticosteroids, IVIG, or rituximab after specialist consultation.
• Neurodegenerative disorders – disease‑modifying agents (e.g., levodopa for Parkinson’s) plus symptomatic autonomic medications.

Pharmacologic options for sudomotor symptoms

• For hypohidrosis
  • Pilocarpine topical gel (2 %); stimulates muscarinic receptors in sweat glands.
  • Oral  bethanechol (rare, used under specialist supervision).
• For hyperhidrosis
  • Topical anticholinergics – glycopyrrolate 0.5 % cream.
  • Oral anticholinergics – oxybutynin 5 mg daily (monitor for dry mouth, constipation).
  • Botulinum toxin type A injections for focal areas – effective in > 80 % of cases (Cleveland Clinic, 2021).
  • Systemic options – clonidine patches for generalized hyperhidrosis.

Procedural and device‑based therapies

• Iontophoresis – controlled electrical current through water for palmar/plantar hyperhidrosis.
• Sympathectomy – thoracic or lumbar surgical interruption of sympathetic nerves; reserved for severe, refractory hyperhidrosis.
• Cooling vests or wearable evaporative devices – assist patients with hypohidrosis during exercise or hot weather.

Lifestyle and supportive measures

• Hydration – aim for 2‑3 L of water daily; consider electrolyte‑rich drinks when sweating is excessive.
• Temperature‑controlled environment – air‑conditioned rooms, fans, and ventilation.
• Compression stockings or thigh‑high support for orthostatic symptoms.
• Regular, moderate aerobic exercise – improves overall autonomic tone.

Living with Quantitative Sudomotor Axon Reflex Test Abnormality

Even when the underlying disease cannot be cured, day‑to‑day strategies can markedly improve quality of life.

Daily management tips

• Skin care – moisturize dry areas with fragrance‑free emollients; avoid harsh soaps that can further impair the skin barrier.
• Foot health – inspect feet daily for cracks, calluses, or infections, especially in hypohidrotic patients with diabetes.
• Clothing choices – breathable, moisture‑wicking fabrics (cotton, bamboo); change socks and underwear at least twice daily if sweating is heavy.
• Meal timing – smaller, frequent meals can reduce post‑prandial sweat spikes.
• Medication timing – take anticholinergic agents at night to minimize daytime dryness and morning dryness.
• Stress reduction – yoga, mindfulness, or biofeedback can lower sympathetic over‑activity that worsens hyperhidrosis.

Monitoring and follow‑up

• Schedule autonomic clinic visits every 6–12 months, or sooner if symptoms change.
• Keep a symptom diary: date, temperature, activity, sweat amount, and any triggers.
• Repeat QSART or TST annually for objective tracking, especially when a disease‑modifying therapy is started.

Prevention

Because the test itself does not cause disease, “prevention” focuses on reducing the risk of the disorders that lead to sudomotor dysfunction.

• Maintain optimal blood glucose (HbA1c < 7 %).
• Adopt a heart‑healthy lifestyle – regular exercise, balanced diet, no tobacco.
• Screen for thyroid disease every 5 years or sooner if symptoms appear.
• Limit chronic alcohol consumption (< 2 drinks/day for men, < 1 drink/day for women).
• Promptly treat infections or inflammatory conditions that could trigger autoimmune autonomic neuropathy.
• Use protective footwear and moisturizers to preserve skin integrity in patients with known hypohidrosis.

Complications

If sudomotor dysfunction is left unaddressed, several downstream problems can arise:

• Heat‑related illness – heat exhaustion, heat stroke, or rhabdomyolysis in hypohidrotic individuals, especially during exercise or hot climates.
• Dermatologic infections – maceration and fungal overgrowth in hyperhidrotic areas.
• Foot ulcerations – particularly in diabetic patients with loss of sweating and sensation.
• Cardiovascular instability – orthostatic hypotension leading to falls, syncope, or fractures.
• Psychological impact – chronic hyperhidrosis is linked with anxiety, depression, and social withdrawal (Journal of Dermatology, 2022).

When to Seek Emergency Care

---

**Sources**: Mayo Clinic. “Autonomic Nervous System Disorders.” 2023; CDC. “Diabetes and Neuropathy.” 2022; NIH National Institute of Neurological Disorders and Stroke. “Small Fiber Neuropathy.” 2024; Cleveland Clinic. “Hyperhidrosis Treatment Guidelines.” 2021; WHO. “Guidelines on Managing Chronic Diseases.” 2022; peer‑reviewed articles from *Journal of the Autonomic Nervous System* and *Diabetes Care*.

```